Experimental cocktail targets Hard-to-Treat brain cancer

NCT ID NCT02203526

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see how well the treatment shrinks tumors. It includes both patients whose cancer has returned and those who have not yet been treated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibrutinib (a targeted drug) combined with chemotherapy (temozolomide, etoposide, doxil, dexamethasone, rituximab)
What this could lead to: If successful, this could point toward a more effective treatment option for primary CNS lymphoma, a rare brain cancer with poor outcomes.
What could go wrong: This is an early Phase 1 trial with only 68 participants, so safety and dosing are still being figured out. The combination of multiple strong drugs may cause significant side effects, and it is not yet known if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.